New non-executive director joins Genomics England Board
Genomics England is pleased to announce the appointment of Dr Sergei Yakneen as a Non-Executive Director on its Board.
Dr Yakneen brings deep expertise in deploying technology effectively for health care and research. He currently serves as Chief Technology Officer at Isomorphic Labs, an AI company redefining drug design. He leads Engineering, Computational Biology, Product and Data Strategy, and plays a key role in advancing the company’s mission to apply cutting-edge AI to healthcare.
Before joining Isomorphic Labs, Sergei served as Senior Vice President and CTO at SOPHiA GENETICS, where he oversaw an AI-based molecular diagnostics platform used in more than 70 countries. His distinguished earlier career also includes launching Amazon.com’s first Canadian software engineering centre and leading technical efforts for the PanCancer Analysis of the Whole Genomes Project, the world’s largest cancer genome analysis initiative.
Sergei holds a PhD in computer science from Heidelberg University and a degree in computer science and mathematics from the University of Toronto.
"Sergei’s appointment strengthens our commitment to innovation that is built on trust and transparency. His expertise in AI and healthcare will help us advance genomic medicine responsibly and at scale, ensuring progress delivers meaningful benefits for patients.”
Baroness Nicola Blackwood
Chair of Genomics England
“I’m honoured to join the Genomics England Board and contribute to its vision of a world where everyone benefits from genomics healthcare. Working in partnership with the NHS, Genomics England is leading the way in integrating cutting-edge science into clinical practice, and I look forward to sharing my experience in AI and technology applied to genomic medicine to help turn cutting-edge science into practical solutions that transform patient care.”
Dr Sergei Yakneen
